Title: | High Prevalence of Hepatitis B Virus Infection Among People With HIV in Rural and Periurban Communities in Botswana |
Authors: | Sharon R Mutenga Bonolo B Phinius Motswedi Anderson Irene Gobe Margaret Mokomane Wonderful T Choga Gorata Mpebe Molly Pretorius-Holme Rosemary Musonda Tendani Gaolathe Mompati Mmalane Roger Shapiro Joseph Makhema Shahin Lockman Vlad Novitsky Max Essex Sikhulile Moyo Simani Gaseitsiwe Department of Applied Biological Sciences and Biotechnology, Faculty of Science and Technology, Midlands State University, Gweru, Zimbabwe. Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana. School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana. Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana. School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana. School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana. School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana. Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.Department of Biological Sciences, Faculty of Sciences, University of Botswana, Gaborone, Botswana. Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA. Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana. Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA. Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana. Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA. Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana. Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA. Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana. Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA. Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA. Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA. Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA. Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA. Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA. |
Keywords: | Africa, Botswana hepatitis B virus human immunodeficiency virus occult HBV |
Issue Date: | 6-Jan-2023 |
Publisher: | Oxford University Press |
Abstract: | Background,We aimed to determine the prevalence of hepatitis B virus (HBV) infection among people with human immunodeficiency virus (PWH) in rural and periurban communities in Botswana.Methods.PWH from a previous population-based study, the Botswana Prevention Combination Project, which enrolled adults in 30 communities across Botswana (2013–2018), were screened for HBV surface antigen (HBsAg) and HBV core antibody (anti-HBc). HBsAg-positive (HBsAg+) samples were further screened for HBV core immunoglobulin M antibodies (anti-HBc immunoglobulin M [IgM]) and HBV e antigen (HBeAg). We quantified HBV viral load on participants who tested positive (n = 148) and negative for HBsAg (n = 381).
Results.Of 3304 participants tested, 271 (8% [95% confidence interval {CI}, 7%–9%]) were HBsAg+ while 1788 (56% [95% CI, 54%–57%]) of 3218 PWH whom we tested had positive anti-HBc. Approximately 88% of HBsAg+ participants were on antiretroviral therapy (ART), 40% and 56% of whom were receiving lamivudine- and tenofovir-containing ART, respectively. Male sex (relative risk ratio [RRR], 1.8 [95% CI, 1.2–2.7]) and the northern geographic region (RRR, 2.5 [95% CI, 1.4–4.7]) were independent predictors of HBV infection (HBsAg+). Of 381 persons with negative HBsAg who were tested for occult HBV, 126 (33% [95% CI, 29%–38%]) had positive HBV DNA. Eleven participants were highly viremic with high HBV viral load while on a lamivudine- or tenofovir-containing regimen. Ten (91%) of these participants also had positive HBeAg serology, while 4 (36%) had positive anti-HBc IgM serology.
Conclusions.The prevalence of HBV was high among PWH in Botswana while on ART regimens with activity against HBV. |
URI: | https://cris.library.msu.ac.zw//handle/11408/5653 |
Appears in Collections: | Research Papers
|